Evidence map›Paper›PMID 36798537›Full record

ArticleInternational journal of tryptophan research : IJTR2023

Endothelial Indoleamine-2,3-Dioxygenase-1 is not Critically Involved in Regulating Antitumor Immunity in the Central Nervous System.

A P Abu Hejleh, K Huck, K Jähne, C L Tan, T V Lanz, L Epping, J K Sonner, S G Meuth, A Henneberg, C A Opitz and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of tryptophan research : IJTR, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

A P Abu HejlehDepartment of Neurology, Mannheim Medical Center, University of Heidelberg, Germany.
K HuckDepartment of Neurology, Mannheim Medical Center, University of Heidelberg, Germany.
K JähneDepartment of Neurology, Mannheim Medical Center, University of Heidelberg, Germany.
C L TanDKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany.
T V LanzDepartment of Neurology, Mannheim Medical Center, University of Heidelberg, Germany.
L EppingDepartment of Neurology with Institute of Translational Neurology, University Hospital Münster, Germany.
J K SonnerInstitute of Neuroimmunology and Multiple Sclerosis, Center for Molecular Neurobiology Hamburg, University Medical Center Hamburg-Eppendorf, Germany.
S G MeuthDepartment of Neurology with Institute of Translational Neurology, University Hospital Münster, Germany.
A HennebergDivision of Metabolic Crosstalk in Cancer, German Consortium of Translational Cancer Research (DKTK) & German Cancer Research Center (DKFZ), Heidelberg, Germany.
C A OpitzDivision of Metabolic Crosstalk in Cancer, German Consortium of Translational Cancer Research (DKTK) & German Cancer Research Center (DKFZ), Heidelberg, Germany.
C Herold-MendeDivision of Neurosurgical Research, Department of Neurosurgery, University Hospital Heidelberg, Germany.
F SahmDepartment of Neuropathology, Heidelberg University Hospital, Germany.
M PlattenDepartment of Neurology, Mannheim Medical Center, University of Heidelberg, Germany.
K SahmDepartment of Neurology, Mannheim Medical Center, University of Heidelberg, Germany.
German Cancer Research Center · DEHeidelberg University · DEUniversity Hospital Münster · DEStanford University · USUniversity Medical Center Hamburg-Eppendorf · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The vascular niche of malignant gliomas is a key compartment that shapes the immunosuppressive brain tumor microenvironment (TME). The blood-brain-barrier (BBB) consisting of specialized endothelial cells (ECs) and perivascular cells forms a tight anatomical and functional barrier critically controlling transmigration and effector function of immune cells. During neuroinflammation and tumor progression, the metabolism of the essential amino acid tryptophan (Trp) to metabolites such as kynurenine has long been identified as an important metabolic pathway suppressing immune responses. Previous studies have demonstrated that indoleamine-2,3-dioxygenase-1 (IDO1), a key rate-limiting enzyme in tryptophan catabolism, is expressed within the TME of high-grade gliomas. Here, we investigate the role of endothelial IDO1 (eIDO1) expression for brain tumor immunity. Single-cell RNA sequencing data revealed that in human glioma tissue, IDO1 is predominantly expressed by activated ECs showing a JAK/STAT signaling pathway-related CXCL11

Indexed as

CNS immunitygliomaIndoleamine-2,3-dioxygenase-1 (IDO1)tumor vasculature

Identifiers

PMID36798537
PMCPMC9926378
OpenAlexW4319750958

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.